Investors of RxSight, Inc. Have Chance to Lead Class Action Lawsuit Following Heavy Losses

RxSight Investors: A Call to Action for Class Action Lawsuit

Investors holding shares of RxSight, Inc. (NASDAQ: RXST) have encountered significant financial losses recently, prompting many to consider legal action. The Robbins Geller Rudman & Dowd LLP law firm is spearheading a class action lawsuit named Makaveev v. RxSight, Inc., No. 25-cv-01596 (C.D. Cal.), designed for investors who purchased or acquired RxSight securities. This could be a pivotal moment for those looking to seek redress.

Overview of the Lawsuit

The class action alleges that RxSight and certain executives violated the Securities Exchange Act of 1934 by making misleading statements about the company's performance and failing to disclose key challenges. Specifically, the lawsuit focuses on three major issues:

1. Adoption Challenges: The company purportedly experienced significant challenges in adoption, leading to a decline in sales and utilization of their products, particularly the light-adjustable intraocular lenses (LAL) critical for cataract surgeries.
2. Overstated Demand: It is claimed that RxSight overstated the demand for their innovative technology, which has raised questions about their revenue forecasts.
3. Financial Guidance: Due to the aforementioned factors, it became apparent that RxSight was unlikely to meet its self-imposed financial targets for the fiscal year 2025, further eroding investor confidence.

On July 8, 2025, RxSight reported its preliminary second quarter financial results, disclosing a dramatic dip in sales of the Light Delivery Devices (LDD) and a decrease in overall revenue. This information triggered a near 38% drop in the value of RxSight's stock.

The Lead Plaintiff Process

For those who incurred losses, the Private Securities Litigation Reform Act of 1995 allows you to take the lead in this class action lawsuit. The lead plaintiff typically has the most significant financial interest in the case at hand and acts on behalf of all other investors in directing the lawsuit. To be considered, investors must file their lead plaintiff motions before September 22, 2025.

Potential lead plaintiffs can choose their attorneys from Robbins Geller, ensuring they have experienced professionals managing their case. Notably, participation as a lead plaintiff does not limit the ability of other investors to recover in the final resolution of the case.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is a preeminent firm specialized in securities fraud litigation, boasting a remarkable track record of securing monetary relief for investors. In the previous year alone, they recovered over $2.5 billion across several securities class actions, establishing themselves as leaders in this field.

The firm’s vast resources include 200 lawyers distributed across 10 offices and they have historically represented clients in some of the largest class action recoveries. Investors seeking more information about the process can visit their site here.

Conclusion

If you have faced substantial financial losses as a result of your investment in RxSight, it is crucial to have your voice heard. Consider the opportunity to lead a class action lawsuit as the September deadline approaches. This initiative not only represents a chance for personal recovery but also serves as a mechanism for holding companies accountable for their actions to investors.

For more information, interested parties can contact Robbins Geller’s attorneys, J.C. Sanchez or Jennifer N. Caringal, at 800-449-4900 or through email at [email protected]. Don’t let your losses go unchecked—take the necessary steps to protect your investments today.